MAHONEY DAVID L

Check this box

if no longer

subject to

Section 16.

Form 4 June 15, 2009

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

Form 4 or Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

See Instruction

1. Name and Address of Reporting Person * MAHONEY DAVID L

(First)

2. Issuer Name and Ticker or Trading

Issuer

Symbol

CORCEPT THERAPEUTICS INC

(Check all applicable)

5. Relationship of Reporting Person(s) to

[CORT]

(Last)

3. Date of Earliest Transaction

X_ Director

10% Owner

C/O CORCEPT

(Middle)

(Month/Day/Year) 06/11/2009

Filed(Month/Day/Year)

Officer (give title

Other (specify

THERAPEUTICS, 149

COMMONWEALTH DRIVE

(Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

MENLO PARK, CA 94025

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Disposed of (D) Code (Instr. 8) (Instr. 3, 4 and 5)

5. Amount of Securities Beneficially Owned Following

Reported

6. Ownership 7. Nature of Form: Direct Indirect (D) or Beneficial Indirect (I)

Ownership (Instr. 4) (Instr. 4)

By Trust

(9-02)

(A)

Transaction(s)

Code V Amount (D) Price

(Instr. 3 and 4)

Common 929,249 I Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: MAHONEY DAVID L - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Numb orDerivativ Securitie Acquired or Dispo (D) (Instr. 3, and 5)	ve s l (A) sed of	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 5						<u>(1)</u>	07/20/2014	Common Stock	60,000
Stock Option (right to buy)	\$ 4.95						<u>(2)</u>	03/02/2016	Common Stock	10,000
Stock option (right to buy)	\$ 2.7						<u>(3)</u>	12/19/2017	Common Stock	30,000
Warrants	\$ 2.77						03/25/2008	03/24/2015	Common Stock	30,534
Stock Option (right to buy)	\$ 2.23						<u>(4)</u>	06/10/2018	Common Stock	30,000
Stock Option (right to buy)	\$ 0.96	06/11/2009		A	50,000		<u>(5)</u>	06/11/2019	Common Stock	50,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
2	Director	10% Owner	Officer	Other		
MAHONEY DAVID L C/O CORCEPT THERAPEUTICS 149 COMMONWEALTH DRIVE MENLO PARK, CA 94025	X					

Reporting Owners 2

Edgar Filing: MAHONEY DAVID L - Form 4

Signatures

/s/ Joseph K. Belanoff, CEO of Corcept Therapeutics Incorporated attorney-in-fact

06/15/2009

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Immediately exercisable subject to a right of repurchase by Corcept Therapeutics Incorporated that shall lapse at the rate of 20% of the total option shares on 7/20/2005 and an additional 1.67% of the total option shares on each monthly anniverary of 7/20/2005.
- (2) Exercisable with respect to 25% of the total number of Option Shares one year after 3/2/2006 and with respect to an additional 2.0834% of the total number of Option Shares on the monthly anniversary of 3/2/2006 each month thereafter.
- (3) Exercisable with respect to 8.3334% of the total options shares on each monthly anniversary of June 11, 2007 so that the entirety of the option grant will vest in one year.
- (4) Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 10, 2008 so that the entirety of the option grant will vest within one year.
- (5) Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 11, 2009 so that the entirety of the option grant will vest on or before the date of Corcept's next Annual Meeting of Stockholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3